Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Medtronic
McKinsey
Johnson and Johnson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NAPROSYN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Naprosyn

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00153660 Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients Unknown status Chinese University of Hong Kong Phase 3 2005-06-01 The aim of this study is to compare a PPI (esomeprazole) plus a COX-2 inhibitor (celecoxib) with a PPI plus a nonselective NSAID (naproxen) in preventing recurrent ulcer bleeding in arthritis patients with a history of ulcer. The investigators hypothesized that among patients with a history of ulcer bleeding who receive prophylaxis with a PPI, celecoxib would be superior to naproxen for the prevention of recurrent ulcer bleeding irrespective of concomitant use of aspirin.
NCT00383487 A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer Terminated Novacea Phase 2 2005-03-01 To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
NCT00383487 A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer Terminated Stanford University Phase 2 2005-03-01 To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
NCT00527904 A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO) Completed POZEN Phase 3 2007-03-01 This study uses an open-label design and will be conducted in approximately 60 sites aiming to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12 months exposure to PN400 (VIMOVO).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Naprosyn

Condition Name

Condition Name for Naprosyn
Intervention Trials
Healthy 4
Osteoarthritis 3
Surgery 2
Rib Fractures 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Naprosyn
Intervention Trials
Migraine Disorders 3
Osteoarthritis 3
Stomach Ulcer 3
Rib Fractures 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Naprosyn

Trials by Country

Trials by Country for Naprosyn
Location Trials
United States 30
Sweden 4
Canada 4
United Kingdom 2
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Naprosyn
Location Trials
New York 2
Maryland 2
North Carolina 2
California 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Naprosyn

Clinical Trial Phase

Clinical Trial Phase for Naprosyn
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Naprosyn
Clinical Trial Phase Trials
Completed 11
Recruiting 6
Unknown status 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Naprosyn

Sponsor Name

Sponsor Name for Naprosyn
Sponsor Trials
AstraZeneca 3
Logical Therapeutics 2
Oxford Pharmascience Ltd 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Naprosyn
Sponsor Trials
Other 17
Industry 13
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts
Moodys
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.